Furthermore, the IMbrave150 trial demonstrated that the combination of atezolizumab (an anti-PD-L1 antibody) and bevacizumab [an anti- vascular endothelial growth factor A (anti- VEGFA) antibody] was superior to sorafenib in the treatment of unresectable HCC. The gene discussed is CD274; the disease is hepatocellular carcinoma.